S&P 500   4,284.37 (+1.50%)
DOW   33,750.34 (+2.08%)
QQQ   354.88 (+0.82%)
AAPL   180.74 (+0.36%)
MSFT   334.34 (+0.53%)
META   274.38 (+0.65%)
GOOGL   125.09 (+1.11%)
AMZN   124.65 (+1.53%)
TSLA   215.98 (+4.08%)
NVDA   394.06 (-0.92%)
NIO   7.71 (+2.25%)
BABA   85.15 (+2.59%)
AMD   118.69 (-0.65%)
T   15.10 (-4.49%)
F   12.44 (+2.73%)
MU   68.67 (-0.61%)
CGC   0.84 (+0.66%)
GE   106.30 (+1.56%)
DIS   91.10 (+2.83%)
AMC   4.56 (+0.22%)
PFE   38.51 (+1.29%)
PYPL   64.25 (+1.90%)
NFLX   404.64 (+0.37%)
S&P 500   4,284.37 (+1.50%)
DOW   33,750.34 (+2.08%)
QQQ   354.88 (+0.82%)
AAPL   180.74 (+0.36%)
MSFT   334.34 (+0.53%)
META   274.38 (+0.65%)
GOOGL   125.09 (+1.11%)
AMZN   124.65 (+1.53%)
TSLA   215.98 (+4.08%)
NVDA   394.06 (-0.92%)
NIO   7.71 (+2.25%)
BABA   85.15 (+2.59%)
AMD   118.69 (-0.65%)
T   15.10 (-4.49%)
F   12.44 (+2.73%)
MU   68.67 (-0.61%)
CGC   0.84 (+0.66%)
GE   106.30 (+1.56%)
DIS   91.10 (+2.83%)
AMC   4.56 (+0.22%)
PFE   38.51 (+1.29%)
PYPL   64.25 (+1.90%)
NFLX   404.64 (+0.37%)
S&P 500   4,284.37 (+1.50%)
DOW   33,750.34 (+2.08%)
QQQ   354.88 (+0.82%)
AAPL   180.74 (+0.36%)
MSFT   334.34 (+0.53%)
META   274.38 (+0.65%)
GOOGL   125.09 (+1.11%)
AMZN   124.65 (+1.53%)
TSLA   215.98 (+4.08%)
NVDA   394.06 (-0.92%)
NIO   7.71 (+2.25%)
BABA   85.15 (+2.59%)
AMD   118.69 (-0.65%)
T   15.10 (-4.49%)
F   12.44 (+2.73%)
MU   68.67 (-0.61%)
CGC   0.84 (+0.66%)
GE   106.30 (+1.56%)
DIS   91.10 (+2.83%)
AMC   4.56 (+0.22%)
PFE   38.51 (+1.29%)
PYPL   64.25 (+1.90%)
NFLX   404.64 (+0.37%)
S&P 500   4,284.37 (+1.50%)
DOW   33,750.34 (+2.08%)
QQQ   354.88 (+0.82%)
AAPL   180.74 (+0.36%)
MSFT   334.34 (+0.53%)
META   274.38 (+0.65%)
GOOGL   125.09 (+1.11%)
AMZN   124.65 (+1.53%)
TSLA   215.98 (+4.08%)
NVDA   394.06 (-0.92%)
NIO   7.71 (+2.25%)
BABA   85.15 (+2.59%)
AMD   118.69 (-0.65%)
T   15.10 (-4.49%)
F   12.44 (+2.73%)
MU   68.67 (-0.61%)
CGC   0.84 (+0.66%)
GE   106.30 (+1.56%)
DIS   91.10 (+2.83%)
AMC   4.56 (+0.22%)
PFE   38.51 (+1.29%)
PYPL   64.25 (+1.90%)
NFLX   404.64 (+0.37%)
NASDAQ:ENOB

Enochian Biosciences (ENOB) Stock Forecast, Price & News

$0.78
-0.04 (-4.89%)
(As of 01:45 PM ET)
Compare
Today's Range
$0.78
$0.88
50-Day Range
$0.82
$1.30
52-Week Range
$0.72
$4.20
Volume
31,577 shs
Average Volume
51,989 shs
Market Capitalization
$45.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

ENOB stock logo

About Enochian Biosciences (NASDAQ:ENOB) Stock

Enochian Biosciences, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. Its pipeline consists of ENOB-HV-01, ENOB- HV-11, ENOB-HV-12, ENOB-DB-01, ENOB-DC-01, ENOB-DC-11, and ENOB-DC-21. The company was founded by Rene Sindlev and Serhat Gumrukcu on January 18, 2011 and is headquartered in Los Angeles, CA.

Receive ENOB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enochian Biosciences and its competitors with MarketBeat's FREE daily newsletter.

ENOB Stock News Headlines

Is Graphite the New Lithium?
Did you know that graphite (NOT lithium) is the largest component of lithium batteries used for EV's? Unfortunately, there are no graphite-producing mines in North America today. This leaves the U.S. at the mercy of China for our vital graphite supply.
Enochian BioSciences’ CEO Letter to Shareholders
The Graphite Shortage Story You're Not Being Told
Graphite demand for EV batteries is expected to increase 10X from 2020 to 2030. And today, with NO graphite-producing mines in N. America, China has a stranglehold on our graphite supply. That's why the U.S. government is spending billions of dollars to ensure an adequate domestic supply of this metal that's vital for energy independence and national security.
ENOB.O - | Stock Price & Latest News | Reuters
Enochian gets Nasdaq notice for delaying crucial filings
Enochian Biosciences, Inc. (ENOB)
Pre-market Movers: ATXG, FWBI, IDYA, ENOB, LUCY…
See More Headlines

ENOB Price History

ENOB Company Calendar

Today
6/02/2023
Next Earnings (Estimated)
6/02/2023
Fiscal Year End
6/30/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ENOB
Fax
N/A
Employees
11
Year Founded
N/A

Profitability

Net Income
$-113,430,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.13 per share

Miscellaneous

Free Float
45,625,000
Market Cap
$45.46 million
Optionable
Not Optionable
Beta
1.22

Key Executives

  • Mark Richard Dybul
    Executive Vice Chairman & Chief Executive Officer
  • François Binette
    Chief Operating Officer
  • Luisa Puche
    Chief Financial Officer & Secretary
  • Greg Duczynski
    Senior Vice President-Clinical Operations
  • Joseph R. Cohen
    Director-Research & Discovery













ENOB Stock - Frequently Asked Questions

How have ENOB shares performed in 2023?

Enochian Biosciences' stock was trading at $1.03 at the beginning of 2023. Since then, ENOB stock has decreased by 24.3% and is now trading at $0.78.
View the best growth stocks for 2023 here
.

Are investors shorting Enochian Biosciences?

Enochian Biosciences saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 1,430,000 shares, a decrease of 6.5% from the April 30th total of 1,530,000 shares. Based on an average daily volume of 58,400 shares, the days-to-cover ratio is presently 24.5 days. Currently, 5.3% of the company's stock are short sold.
View Enochian Biosciences' Short Interest
.

When is Enochian Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, June 2nd 2023.
View our ENOB earnings forecast
.

What other stocks do shareholders of Enochian Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Enochian Biosciences investors own include AcelRx Pharmaceuticals (ACRX), Aptinyx (APTX), Axcella Health (AXLA), Aytu BioPharma (AYTU), Calithera Biosciences (CALA), Cidara Therapeutics (CDTX), Catalyst Pharmaceuticals (CPRX), DURECT (DRRX), Geron (GERN) and

What is Enochian Biosciences' stock symbol?

Enochian Biosciences trades on the NASDAQ under the ticker symbol "ENOB."

Who are Enochian Biosciences' major shareholders?

Enochian Biosciences' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (2.21%), Two Sigma Advisers LP (0.10%), Two Sigma Investments LP (0.10%), HRT Financial LP (0.07%) and Belvedere Trading LLC (0.00%). Insiders that own company stock include Carl Forest Sandler and Serhat Gumrukcu.
View institutional ownership trends
.

How do I buy shares of Enochian Biosciences?

Shares of ENOB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Enochian Biosciences' stock price today?

One share of ENOB stock can currently be purchased for approximately $0.78.

How much money does Enochian Biosciences make?

Enochian Biosciences (NASDAQ:ENOB) has a market capitalization of $45.46 million. The company earns $-113,430,000.00 in net income (profit) each year or ($0.82) on an earnings per share basis.

How can I contact Enochian Biosciences?

Enochian Biosciences' mailing address is 2080 Century Park EastSuite 906, Los Angeles CA, 90067. The official website for the company is www.enochianbio.com. The company can be reached via phone at (305) 918-1980 or via email at ir@enochianbio.com.

This page (NASDAQ:ENOB) was last updated on 6/2/2023 by MarketBeat.com Staff

My Account -